Dopamine Transporter SPECT Imaging in Parkinson Disease and Dementia

被引：4
作者：
Surasi, Devaki Shilpa [1 ]
Peller, Patrick J. [2 ]
Szabo, Zsolt [3 ]
Mercier, Gustavo [4 ]
Subramaniam, Rathan M. [3 ]
机构：
[1] Univ Alabama Birmingham, Dept Radiol, Birmingham, AL 35249 USA
[2] Mayo Clin, Dept Radiol, Rochester, MN 55902 USA
[3] Johns Hopkins Med Inst, Russel H Morgan Dept Radiol & Radiol Sci, Baltimore, MD 21287 USA
[4] Boston Univ, Dept Radiol, Boston, MA 02118 USA
来源：
PET CLINICS | 2013年 / 8卷 / 04期
关键词：
Parkinson disease; Dopamine; SPECT; Dementia;
D O I：
10.1016/j.cpet.2013.08.006
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
The clinical diagnosis of Parkinson disease (PD) is difficult, as several other neurodegenerative and basal ganglia disorders have similar clinical presentations. Dopamine transporter single-photon emission computed tomography has been proposed as possible diagnostic tool to help differentiate idiopathic PD from essential tremor and other disorders that present with parkinsonian symptoms. In addition, it is valuable in the diagnosis of dementia with Lewy bodies, differentiating it from other causes of dementia such as Alzheimer disease.
引用
收藏
页码：459 / +
页数：10
相关论文
共 46 条
  • [1] Gelb D.J., Oliver E., Gilman S., Diagnostic criteria for Parkinson disease, Archives of Neurology, 56, 1, pp. 33-39, (1999)
  • [2] Tanner C.M., Goldman S.M., Epidemiology of Parkinson's disease, Neurol Clin, 14, 2, pp. 317-335, (1996)
  • [3] Marsden C.D., Parkinson's disease, J Neurol Neurosurg Psychiatr, 57, 6, pp. 672-681, (1994)
  • [4] Hague S.M., Klaffke S., Bandmann O., Neurodegenerative disorders: Parkinson's disease and Huntington's disease, Journal of Neurology, Neurosurgery and Psychiatry, 76, 8, pp. 1058-1063, (2005)
  • [5] Neumeyer J.L., Wang S., Gao Y., Milius R.A., Kula N.S., Campbell A., Baldessarini R.J., Zea-Ponce Y., Baldwin R.M., Innis R.B., N-fluoroalkyl analogs of (1R)-2β-carbomethoxy-3β-(4-iodophenyl) - tropane (β-CIT): Radiotracers for positron emission tomography and single photon emission computed tomography imaging of dopamine transporters, Journal of Medicinal Chemistry, 37, 11, pp. 1558-1561, (1994)
  • [6] Marvin M., Goldenberg P.T., Pharmaceutical Approval Update, 36, 3, pp. 162-164, (2011)
  • [7] Ciliax B.J., Heilman C., Demchyshyn L.L., Et al., The dopamine transporter: Immunochemical characterization and localization in brain, J Neurosci, 15, 3 PART 1, pp. 1714-1723, (1995)
  • [8] Kish S.J., Shannak K., Hornykiewicz O., Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications, New England Journal of Medicine, 318, 14, pp. 876-880, (1988)
  • [9] Varrone A., Sansone V., Pellecchia M.T., Et al., Comparison between a dual-head and a brain-dedicated SPECT system in the measurement of the loss of dopamine transporters with [123I]FP-CIT, Eur J Nucl Med Mol Imaging, 35, 7, pp. 1343-1349, (2008)
  • [10] Darcourt J., Booij J., Tatsch K., Et al., EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version, Eur J Nucl Med Mol Imaging, 37, 2, pp. 443-450, (2010)
12345